SWOG clinical trial number
CTSU/EA2201

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Open
Phase
II
Abbreviated Title
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status Notes
May Thet Cho, MD SWOG Champion
Activated
05/13/2021

Research committees

Gastrointestinal Cancer

Treatment

Ipilimumab Nivolumab

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2022

EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors

K Ciombor;S Hong;C Eng;X Yao;M Thet Cho;YN You;P Das;A Chakravarthy;P O'Dwyer J Clin Oncol 40, 2022 (suppl 16; abstr TPS3644), poster 430A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session

Other Clinical Trials